The Effect of Bisoprolol on Heart Failure Preserved Ejection Fraction / Hfpef Patient’s Quality Of Life

Background: Global Public Health Burden of Heart Failure reported the growing prevalence of heart failure which is 64.3 million affected in 2020 worldwide with half of the case classified as Heart Failure Preserved Ejection Fraction (HFpEF). It is well known that someone who has been diagnosed with heart failure will have a poorer quality of life/QoL. β-blocker is a heart rate lowering agent with a potency to improve the patient’s clinical outcomes, one of them is QoL. Objective: This study aimed to observe and evaluate the effect of bisoprolol, a type of β-blocker, in the improve-ment of HFpEF patient’s QoL. Method: This study is a retrospective cohort following HFpEF patients who received bisoprolol and HFpEF patients who did not receive bisoprolol. The study participants were selected using purposive sampling method. Result: Our study found that from all HFpEF patients who received bisoprolol 102 patients had a good QoL and 2 patients had a poor QoL (p=0.000) according to Minnesota Living With Heart Failure Questionnaire (MLHFQ). The median physical score in the patient who did not receive bisoprolol was 10 while the median score of the patient who received β-blocker was 4 (p=0.000). The mean emotional score for the patients who did not receive β-blocker was 3 while the mean score of the patients who received β-blocker was 1 (p=0.000). Conclusion: We conclude that the use of bisoprolol could improve the HFpEF patient’s QoL evaluated by total score, physical score, and emotional score.